Clinical Trial Detail

NCT ID NCT02130466
Title A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Trametinib

Pembrolizumab + Trametinib

Dabrafenib + Pembrolizumab

Dabrafenib + Pembrolizumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST